Skip to main content

Taggar

andningsvägar

cancer

diabetes

forskning & utveckling

hjärta/kärl

ledning

mage/tarm

neurovetenskap

AstraZeneca 225 cancer 189 forskning & utveckling 138 hjärta/kärl 123 diabetes 76 andningsvägar 57 mage/tarm 18 neurovetenskap 16 FDA 10 onkologi 9 infektion 7 astma 7 delårsrapport 7 seroquel 7 Observationsstudie 6 forxiga 6 forskning 6 akut kranskärlssjudom 6 medimmune 6 RWE 5 naloxegol 5 vandetanib 5 ledning 5 motavizumab 5 bokslutsrapport 5 Tagrisso 5 influensavaccin 5 egfr-testning 5 karolinska institutet 4 fostamatinib 4 fluenz 4 ledgångsreumatism 4 bristol-myers squibb 4 antibiotika 4 olaparib 4 lungcancer 4 seroquel xr 4 tc-5214 4 crestor® 3 slusg 3 antibiotikaresistens 3 CVD-REAL 3 astra tech 3 kroniskt obstruktiv lungsjukdom 3 osimertinib 3 anders ekblom 3 vimovo 3 japan 3 styrelsen 3 pathos 3 gefitinib 3 produkt 3 selumetinib 3 egentlig depression 3 subvention 3 klopidogrel 2 opioider 2 tyskland 2 kvartalsrapport 2 individanpassad behandling 2 almedalen 2 seroquel xr (quetiapin fumarat) 2 entocort 2 axanum 2 patenttvist 2 astrazenca 2 samarbete 2 typ2diabetes 2 ardea biosciences 2 produktion 2 life science 2 seroquel xl 2 dapagliflozin 2 acalabrutinib 2 targacept 2 byetta 2 benralizumab 2 recentin 2 slusg stipendium 2 smärta 2 bydureon 2 registerstudie 2 kina 2 epanova 2 saturn 2 corporate 2 återfall 2 Brilique 2 ticagrelor 2 läkemedelsförmånen 2 mdd 2 Real World evidence 2 caprelsa 2 fulvestrant 2 confirm 2 produktionsanläggning 1 ema 1 gikt 1 cardiologföreningen 1 ovarian cancer 1 merck-avtal 1 savor 1 årsredovisning 2010 1 non-executive director 1 iressa 1 nytt läkemedel mot lungcancer 1 behandling lungcancer 1 målstyrt läkemedel 1 EGFR 1 nytt läkemedel lungcancer 1 cediranib 1 bevacizumab 1 scilifelab 1 yngre forskare 1 päivi tolstoy 1 tobias ankner 1 hans andersson 1 syntetisk kemi 1 torrent pharma 1 varumärkta generika 1 saxagliptin 1 blodsockerkontroll 1 blodsockerfall 1 viktökning 1 esc 1 ldl-c 1 gonorré 1 sepsis 1 livskvalitet lungcancer 1 ipass 1 lungcancersymtom 1 mcrc 1 complete response letter (crl) 1 u.s. food and drug administration (fda) 1 generiskt esomeprazolmagnesium 1 kanadensiska hälsovårdsministeriet 1 apotex inc (notice of compliance 1 noc) 1 internationell konkurrens 1 nikotinkanalsblockerare 1 läkemedel 1 DAISY 1 subventioner 1 UCR 1 zibotentan 1 biokemiska markörer 1 egfr-muterad 1 cytofab 1 azd9773 1 eurika 1 kombiglyze xr 1 klinisk forsk 1 pegasus 1 produktionschef 1 AI 1 berzeliussamlingen 1 nya läkemedel 1 right honourable baroness shriti vadera 1 certriad 1 astrazeneca lund 1 arbetsmarknadsdagar 1 registreringsansökan 1 kastrationsresistent 1 fas 3-studie 1 hormonresistent 1 budesonid 1 mobil-app 1 opioidbehandling 1 nktr-118 1 forskningsportfölj 1 skatteärende 1 denosumab 1 amylin 1 patologi 1 NSCLC 1 egfr mutation 1 egfr positiv 1 komboglyze 1 caz-avi 1 hälsoekonomiska data 1 delårsrapport januari-september 2011 1 typ-1 diabetes 1 patientundersökning 1 david brennan 1 hudinfektioner 1 medicon village 1 translationell 1 illumina 1 årsredovisning 2011 1 antibiotikum 1 flumist 1 kvadrivalent 1 quetiapin fumarat 1 citizen petitions 1 renaissance 4 1 renaissance 5 1 formuleringspatent 1 citizens petition 1 prismodell 1 lesinurab 1 the medicines company 1 nda 1 amend 1 amylin pharmaceuticals 1 mdr-tb 1 mikael agaton 1 grymt fett 1 tonårshjärnan 1 per hamid ghatan 1 grymt fett en filmserie om tonårshjärnan 1 exacerbationer 1 pascal soriot 1 säsongsinfluensavaccin för barn som nässpray 1 säsongsinfluencavaccin 1 barninfluensavaccin 1 nässprayvaccin 1 influensanässpray 1 jonas bergh 1 bröstcancer utmärkelse 2012 1 sjukhusinfektioner 1 zinforo 1 mjukdelsinfektioner 1 ceftarolinfosamil 1 max planck institute 1 magnus björsne 1 per alfredsson 1 remissvar prismodell 1 pris läkemedel 1 strategiska centra 1 forsknings - och utvecklingscentra 1 bioläkemedel 1 tre strategiska centra 1 aks 1 exenatide 1 glp-1 agonister 1 cancerregister 1 svenska lungcancerstudiegruppen 1 non-small-cell lungcancer 1 motivationsstöd 1 patient websida 1 sekundärprevention 1 patientstöd 1 fluenz tetra 1 metreleptin 1 lipodystrofi 1 lesinurad 1 farxiga 1 xigduo 1 myalept 1 ann cairns 1 akuta koronara syndrom 1 metabola sjukdomar 1 immunoterapier 1 advaxis 1 sommarforskarskola 1 non-small cell lung cancer 1 astma/kol 1 gensekvensering 1 oic 1 hjärt-och kärlsjukdom 1 hjärinfarkt 1 biohub 1 bioventurehub 1 elisabeth björk 1 antaros 1 hha 1 healthy heart africa 1 världsdiabetesdagen 2014 1 moventig 1 Lynparza 1 opioidorsakad 1 pegasus-timi 1 e-brilique 1 Uppsala Clinical Research Center 1 mobiltelefonapplikation 1 SUPPORT-studien 1 ordnat införande Almedalen 1 QTERN 1 Zavicefta 1 moderna therapeutics 1 SvFP 1 kyntheum 1 brodalumab 1 Imfinzi 1 durvalumab 1 CVD-REAL Nordic 1 osimertinub 1 världsastmadagen 1 PACEHR 1 svår astma 1 Katarina Ageborg 1 norge 1 VD AstraZeneca Sverige AB 1 innovation 1 eu 1 sponsring 1 patent 1 lund 1 forskare 1 stipendier 1 usa 1 hjärtinfarkt 1 stroke 1 kol 1 influensa 1 depression 1 antidepressiva läkemedel 1 tlv 1 beslut 1 alzheimers 1 äggstockscancer 1 södertälje 1 högkostnadsskyddet 1 collaboration 1 halvårsrapport 1 forskarstipendium 1 schizofreni 1 merck 1 läkemedelsforskning 1 pfizer 1 psoriasis 1 bakterier 1 karolinska universitetssjukhuset 1 artros 1 pa 1 delårsrapport januari - mars 1 h1n1 1 r&d 1 mölndal 1 generiska läkemedel 1 typ 2-diabetes 1 styrelseordförande 1 gener 1 apollo 1 hälsoekonomi 1 halvårsresultat 1 pet 1 mrsa 1 ny indikation 1 diagnostik 1 förstoppning 1 kranskärlsjukdom 1 invasiv behandling 1 journal of clinical oncology 1 avancerad hormonkänslig bröstcancer 1 first studien 1 asco 1 konkurrenskraften 1 läkemedelsforskningen 1 forskarkarriärer 1 stipendieprogram 1 rosuvastatinkalcium 1 hyperkolesterolemi 1 pluto-studien 1 vimovotm 1 nsaid 1 pozen 1 sumitomo 1 american college of rheumatology 1 2009 annual scientific meeting in philadelphia 1 leif johansson 1 zactima (vandetanib) 1 toprol-xl 1 vaccinet 1 inflammation 1 jan lundberg 1 stemi 1 rosuvastatin 1 arimidex 1 anastrozol 1 atac 1 bypass 1 kolorektalcancer 1 sjukhussjuka 1 avancerad bröstcancer 1 avastin 1 kvalitetsregister 1 blodförgiftning 1 ämnesomsättningssjukdomar 1 jupiter-studien 1 ämnesomsättningssjukdomar (emdac) 1 jupiter 1 faslodex (fulvestrant) 1 monoterapi 1 den amerikanska läkemedelsmyndigheten 1 skelettmetastaser 1 roger henriksson 1 Visa alla taggar
Selumetinib granted orphan drug designation in Japan for neurofibromatosis type 1

Selumetinib granted orphan drug designation in Japan for neurofibromatosis type 1

Pressmeddelanden   •   Jun 30, 2020 08:04 CEST

AstraZeneca today announced that selumetinib has been granted orphan drug designation (ODD) in Japan for the treatment of neurofibromatosis type 1 (NF1), a rare and debilitating genetic disease.

AstraZenecas BioVentureHub och Mölnlycke inleder samarbete för att stödja kunskapsutbytet inom svensk life science-industri

AstraZenecas BioVentureHub och Mölnlycke inleder samarbete för att stödja kunskapsutbytet inom svensk life science-industri

Pressmeddelanden   •   Jun 25, 2020 08:00 CEST

AstraZeneca meddelar idag att företagets BioVentureHub har ingått ett nytt samarbete med Mölnlycke, ett globalt medicinteknikföretag med huvudkontor i Göteborg. Samarbetet innebär att små och medelstora företag (SME) anslutna till AstraZenecas BioVentureHub kommer att erbjudas gratis konsultationer med Mölnlyckes experter för att utveckla produkter och lösningar med medicintekniska komponenter.

Breztri Aerosphere significantly reduced rate of moderate  or severe COPD exacerbations in Phase III ETHOS trial

Breztri Aerosphere significantly reduced rate of moderate or severe COPD exacerbations in Phase III ETHOS trial

Pressmeddelanden   •   Jun 24, 2020 20:18 CEST

Full results from the positive Phase III ETHOS trial showed AstraZeneca’s triple-combination therapy Breztri Aerosphere (budesonide/glycopyrronium/formoterol fumarate) demonstrated a statistically significant reduction in the rate of moderate or severe exacerbations compared with two dual-combination therapies in patients with moderate to very severe chronic obstructive pulmonary disease (COPD).

AstraZeneca to supply Europe with up to 400 million doses of Oxford University’s vaccine at no profit

AstraZeneca to supply Europe with up to 400 million doses of Oxford University’s vaccine at no profit

Pressmeddelanden   •   Jun 13, 2020 15:10 CEST

AstraZeneca has reached an agreement with Europe’s Inclusive Vaccines Alliance (IVA), spearheaded by Germany, France, Italy and the Netherlands, to supply up to 400 million doses of the University of Oxford’s COVID-19 vaccine, with deliveries starting by the end of 2020.

Calquence showed long-term efficacy and tolerability for patients with chronic lymphocytic leukaemia in two trials

Calquence showed long-term efficacy and tolerability for patients with chronic lymphocytic leukaemia in two trials

Pressmeddelanden   •   Jun 12, 2020 08:32 CEST

Detailed results from both the Phase II ACE-CL-001 trial and the pivotal Phase III ASCEND trial showed the long-term efficacy and tolerability of Calquence (acalabrutinib) in chronic lymphocytic leukaemia (CLL), one of the most common types of adult leukaemia

AstraZeneca to showcase leadership in treating type-2 diabetes and cardiorenal complications at ADA 2020

AstraZeneca to showcase leadership in treating type-2 diabetes and cardiorenal complications at ADA 2020

Pressmeddelanden   •   Jun 11, 2020 08:01 CEST

AstraZeneca will present new data from the landmark Phase III DAPA-HF and DECLARE-TIMI 58 trials at the upcoming 80th American Diabetes Association (ADA) Virtual Scientific Sessions, 12-16 June 2020. The data are among 23 accepted abstracts.....

Calquence showed promising clinical improvement in majority of 19 hospitalised COVID-19 patients

Calquence showed promising clinical improvement in majority of 19 hospitalised COVID-19 patients

Pressmeddelanden   •   Jun 05, 2020 20:39 CEST

Results published in Science Immunology showed that Calquence (acalabrutinib), a Bruton’s tyrosine kinase (BTK) inhibitor, reduced markers of inflammation and improved clinical outcomes of patients with severe COVID-19 disease.1

AstraZeneca presents new data across continuum of care from its broad renal portfolio at ERA-EDTA 2020 Virtual Congress

AstraZeneca presents new data across continuum of care from its broad renal portfolio at ERA-EDTA 2020 Virtual Congress

Pressmeddelanden   •   Jun 05, 2020 08:01 CEST

AstraZeneca will present new data across its broad portfolio of renal medicines. The 20 abstracts being presented, will include data on Lokelma (sodium zirconium cyclosilicate), roxadustat and Farxiga (dapagliflozin) across different stages of chronic kidney disease (CKD) and AstraZeneca’s ongoing commitment to exploring treatment options across the full continuum of renal care.

AstraZeneca takes next steps towards broad and equitable access to Oxford University’s COVID-19 vaccine

AstraZeneca takes next steps towards broad and equitable access to Oxford University’s COVID-19 vaccine

Pressmeddelanden   •   Jun 04, 2020 17:01 CEST

AstraZeneca has taken the next steps in its commitment to broad and equitable global access to the University of Oxford’s COVID-19 vaccine, following landmark agreements with the Coalition for Epidemic Preparedness Innovations (CEPI), Gavi the Vaccine Alliance, and the Serum Institute of India (SII).

AstraZeneca to discover and develop novel therapies targeting RNA-modifying proteins in oncology collaboration with Accent Therapeutics
Brilinta approved in the US to reduce the risk of a first heart attack or stroke in high-risk patients with coronary artery disease

Brilinta approved in the US to reduce the risk of a first heart attack or stroke in high-risk patients with coronary artery disease

Pressmeddelanden   •   Jun 01, 2020 08:03 CEST

AstraZeneca’s Brilinta (ticagrelor) has been approved in the US to reduce the risk of a first heart attack or stroke in high-risk patients with coronary artery disease (CAD), the most common type of heart disease.

Lynparza recommended for approval in EU by CHMP for BRCA-mutated metastatic pancreatic cancer

Lynparza recommended for approval in EU by CHMP for BRCA-mutated metastatic pancreatic cancer

Pressmeddelanden   •   Jun 01, 2020 08:03 CEST

​AstraZeneca and MSD Inc., Kenilworth, N.J., US (MSD: known as Merck & Co., Inc. inside the US and Canada) today announced that Lynparza (olaparib) has been recommended for marketing authorisation in the European Union (EU) for the 1st-line maintenance treatment of patients with germline BRCA-mutated (gBRCAm) metastatic pancreatic cancer.

Imfinzi plus tremelimumab demonstrated promising clinical  activity and tolerability in patients with advanced liver cancer

Imfinzi plus tremelimumab demonstrated promising clinical activity and tolerability in patients with advanced liver cancer

Pressmeddelanden   •   Maj 29, 2020 14:56 CEST

Results from the global Phase II Study 22 trial testing AstraZeneca’s tremelimumab, an anti-CTLA4 antibody, added to Imfinzi (durvalumab) demonstrated promising clinical activity and tolerability in patients with advanced hepatocellular carcinoma (HCC). HCC is the most common type of liver cancer.1

Enhertu achieved a tumour response rate of 45.3% in patients with HER2-positive metastatic colorectal cancer in Phase II DESTINY-CRC01 trial

Enhertu achieved a tumour response rate of 45.3% in patients with HER2-positive metastatic colorectal cancer in Phase II DESTINY-CRC01 trial

Pressmeddelanden   •   Maj 29, 2020 14:53 CEST

Results from the Phase II DESTINY-CRC01 trial of AstraZeneca and Daiichi Sankyo Company, Limited (Daiichi Sankyo)’s Enhertu (trastuzumab deruxtecan) demonstrated clinically meaningful activity in patients with HER2-positive unresectable and/or metastatic colorectal cancer who received at least two prior lines of standard treatment.

Enhertu demonstrated meaningful clinical activity in patients with HER2-mutant non-small cell lung cancer in interim analysis of Phase II  DESTINY-Lung01 trial

Enhertu demonstrated meaningful clinical activity in patients with HER2-mutant non-small cell lung cancer in interim analysis of Phase II DESTINY-Lung01 trial

Pressmeddelanden   •   Maj 29, 2020 14:42 CEST

Results from the ongoing Phase II DESTINY-Lung01 trial showed AstraZeneca and Daiichi Sankyo Company, Limited (Daiichi Sankyo)’s Enhertu (trastuzumab deruxtecan) achieved a clinically meaningful tumour response in patients with HER2-mutant (HER2m) unresectable and/or metastatic non-squamous non-small cell lung cancer (NSCLC) whose disease had progressed following one or more systemic therapies.

Enhertu significantly improved tumour response rate and overall survival in HER2-positive metastatic gastric cancer in Phase II DESTINY-Gastric01 trial

Enhertu significantly improved tumour response rate and overall survival in HER2-positive metastatic gastric cancer in Phase II DESTINY-Gastric01 trial

Pressmeddelanden   •   Maj 29, 2020 14:09 CEST

Detailed results from the positive, registrational, randomised controlled Phase II DESTINY-Gastric01 trial showed AstraZeneca and Daiichi Sankyo Company, Limited (Daiichi Sankyo)’s Enhertu (trastuzumab deruxtecan) demonstrated a statistically significant and clinically meaningful improvement in objective response rate (ORR) and overall survival (OS), a key secondary endpoint, versus chemotherapy.

Imfinzi showed a sustained overall survival benefit in 1st-line  extensive-stage small cell lung cancer in the Phase III CASPIAN trial

Imfinzi showed a sustained overall survival benefit in 1st-line extensive-stage small cell lung cancer in the Phase III CASPIAN trial

Pressmeddelanden   •   Maj 29, 2020 14:03 CEST

Detailed results from an updated analysis of the Phase III CASPIAN trial showed AstraZeneca’s Imfinzi (durvalumab) in combination with a choice of chemotherapies, etoposide plus either carboplatin or cisplatin, demonstrated a sustained, clinically meaningful overall survival (OS) benefit for adults with extensive-stage small cell lung cancer (ES-SCLC) treated in the 1st-line setting.

Tagrisso demonstrated unprecedented disease-free survival in the adjuvant treatment of Stage IB-IIIA patients with EGFR-mutated lung cancer

Tagrisso demonstrated unprecedented disease-free survival in the adjuvant treatment of Stage IB-IIIA patients with EGFR-mutated lung cancer

Pressmeddelanden   •   Maj 28, 2020 23:03 CEST

Detailed results from the Phase III ADAURA trial showed AstraZeneca’s Tagrisso (osimertinib) demonstrated a statistically significant and clinically meaningful improvement in disease-free survival (DFS) in the adjuvant treatment of patients with early-stage (IB, II and IIIA) epidermal growth factor receptor-mutated (EGFRm) non-small cell lung cancer (NSCLC) ......

AstraZeneca collaborates with ArcherDX to use personalised cancer assays  to detect minimal residual disease in lung cancer trials
Enhertu granted Orphan Drug Designation in the US for gastric cancer

Enhertu granted Orphan Drug Designation in the US for gastric cancer

Pressmeddelanden   •   Maj 22, 2020 08:09 CEST

AstraZeneca and Daiichi Sankyo Company, Limited (Daiichi Sankyo)’s Enhertu (trastuzumab deruxtecan) has been granted Orphan Drug Designation (ODD) in the US for the treatment of patients with gastric cancer, including gastroesophageal junction cancer.